Biocon and Indian Pharma Companies: R&D Challenges Revealed in IIFL Securities Report
Monday, 21 October 2024, 01:45
Current State of Indian Pharma Companies
According to the IIFL Securities Report, Indian pharma companies, including Biocon, are increasingly lagging in key areas of R&D. The findings suggest a notable gap in comparison to their global counterparts, particularly regarding patents and publications.
Disparity in Publications
- The report indicates that the largest disparity was observed in the number of publications per billion USD revenue.
- Global pharmaceutical firms produced approximately 8.4 times more publications than Indian companies.
Industry Implications
This data serves as a crucial reminder of the urgent need for a proactive approach within the industry. Companies like Dr. Reddy's Laboratories and Sun Pharmaceuticals must enhance their focus on innovation and R&D to keep up.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.